Are you curious about where to find the best GC101 factories in China? With so many options available, it’s crucial to know which ones stand out in quality and reliability. Comparing top factories not only saves you time but also ensures you make informed decisions that can significantly impact your business. Imagine having access to the best manufacturers that meet your specific needs, enhancing your product quality and boosting your brand’s reputation. Ready to discover the top contenders? Let’s dive in and explore the leading GC101 factories that could be your next great partnership!
GC101 in SMA II – Clinical Trials Registry – ICH GCP
Product Details: GC101 is a gene therapy drug designed for the treatment of Spinal Muscular Atrophy (SMA) Type 2 patients through intrathecal delivery.
Technical Parameters:
– Self-complementary AAV9 carrying a codon-optimized SMN coding sequence (coSMN1)
– Delivered one-time intrathecally at varying doses (1.2×10^14 vg/person, 2.4×10^1…
Application Scenarios:
– Treatment of Spinal Muscular Atrophy Type 2 in children aged 6 to 60 months
– Clinical trials evaluating safety and efficacy of gene therapy
Pros:
– Potential to improve motor milestones in SMA Type 2 patients
– Long-term follow-up study to assess sustained efficacy and safety
Cons:
– Exclusion of patients with prior gene therapy or specific treatments
– Potential adverse events and serious adverse events during treatment
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment …
Product Details: GC101 gene therapy drug for the treatment of Spinal Muscular Atrophy Type 3 (SMA 3).
Technical Parameters:
– Intrathecal delivery
– Single dose of 1.2×10^14 vg/person
Application Scenarios:
– Patients aged ≥ 2 years with genetic and clinical diagnosis of type 3 SMA.
– Patients with HFMSE score between 10 and 54 at screening.
Pros:
– Evaluates safety and efficacy over a 5-year follow-up.
– Conducted in multiple centers in China.
Cons:
– Excludes patients with certain medical conditions and previous gene therapy tria…
– Requires effective contraceptive measures for female patients of childbearing ag…
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment …
Product Details: GC101 gene therapy drug for the treatment of spinal muscular atrophy Type 1 (SMA 1).
Technical Parameters:
– Intrathecal delivery
– Dose-escalation clinical trial
Application Scenarios:
– Treatment of SMA 1 patients
– Clinical trials in multiple centers
Pros:
– Evaluates safety and efficacy of gene therapy
– Long-term follow-up study of 5 years
Cons:
– Exclusion of patients with previous gene therapy trials
– Potential adverse effects from intrathecal administration
GC101 in Spinal Muscular Atrophy – Clinical Trials Registry – ICH GCP
Product Details: GC101 is a gene therapy drug designed for the treatment of Spinal Muscular Atrophy (SMA) Type 1 patients through intrathecal delivery.
Technical Parameters:
– Self-complementary AAV9 carrying a codon-optimized SMN coding sequence (coSMN1)
– Dosage: Low dosage group – 2.4×10^14 vg/person; High dosage group – 4.8×10^14 vg…
Application Scenarios:
– Treatment of Spinal Muscular Atrophy Type 1 in children
– Clinical trials for evaluating safety and efficacy of gene therapy
Pros:
– Potential to improve motor milestones in SMA Type 1 patients
– Long-term follow-up study to assess sustained efficacy
Cons:
– Exclusion of patients with certain prior treatments or conditions
– Limited to specific age group (six months of age and younger)
Genecradle Therapeutics’ GC101 Injection Recognized as a Breakthrough …
Product Details: GC101 injection is an AAV gene therapy product for intrathecal administration to treat Type 1, Type 2, and Type 3 spinal muscular atrophy (SMA).
Technical Parameters:
– Recombinant serotype 9 adeno-associated virus vector (rAAV9)
– One-time intrathecal injection
Application Scenarios:
– Treatment of Type 1 SMA
– Treatment of Type 2 SMA
– Treatment of Type 3 SMA
Pros:
– Significant therapeutic effects and achievement of new motor milestones
– One-time treatment with long-term efficacy
Cons:
– Potential for complications from SMA
– Limited to specific types of SMA
获批关键II期临床，君赛GC101 TIL疗法更安全、更优效医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Product Details: GC101 TIL注射液，君赛生物研发的天然TIL细胞疗法，针对晚期黑色素瘤患者。
Technical Parameters:
– 无需清淋
– 无需IL-2注射
Application Scenarios:
– 晚期黑色素瘤患者
– 实体瘤细胞治疗
Pros:
– 更安全
– 更优效
Cons:
– 信息不足
– 信息不足
GC-101 by Shanghai Juncell Therapeutics for Metastatic Melanoma …
Product Details: GC-101 is under clinical development by Shanghai Juncell Therapeutics for the treatment of metastatic melanoma.
Technical Parameters:
– Phase II clinical trial
– Administered through parenteral and intravenous route
Application Scenarios:
– Treatment of metastatic melanoma
– Potential use in other solid tumors
Pros:
– Developed using autologous tumor infiltrating lymphocytes (TILs)
– 36% phase transition success rate for Phase II drugs in this indication
Cons:
– Currently in Phase II, not yet approved
– Limited information on long-term efficacy and safety
Chinese Medical Journal – LWW
Product Details: GC101 is a single-dose AAV9-mediated gene therapy for treating SMA type 1 infants via intrathecal injection.
Technical Parameters:
– AAV9 vector containing codon-optimized human SMN1 cDNA
– Administered as a one-time intrathecal injection of 2.4 × 10^14 vector genomes p…
Application Scenarios:
– Treatment of infants diagnosed with SMA type 1
– Clinical trials for gene therapy efficacy and safety
Pros:
– Demonstrated safety with all adverse events being Grade I or II
– Early and sustained improvement in motor function as assessed by CHOP-INTEND
Cons:
– Limited sample size in the study
– Potential confounding factors due to prior treatments with nusinersen
Treatment of SMA type 1 infants using a single-dose AAV9 … – MedNexus
Product Details: Generic product details placeholder
Technical Parameters:
– Generic technical parameter 1
– Generic technical parameter 2
Application Scenarios:
– Generic application scenario 1
– Generic application scenario 2
Pros:
– Generic pro 1
– Generic pro 2
Cons:
– Generic con 1
– Generic con 2
Pill Finder: GC 101 White Round – Medicine.com
Product Details: Acetaminophen 325 mg, white round pill with imprint GC 101.
Technical Parameters:
– Strength: 325 mg
– Color: White
– Shape: Round
– Availability: Rx and/or OTC
Application Scenarios:
– Chiari Malformation
– Dengue Fever
– Eustachian Tube Dysfunction
– Fever
– Muscle Pain
– Neck Pain
– Pain
– Plantar Fasciitis
– Sciatica
– Transverse Myelitis
– Headache
– Back Pain
– Chronic Pain
Pros:
– Widely used for pain relief.
– Available both by prescription and over-the-counter.
Cons:
– May cause liver damage if overdosed.
– Not suitable for individuals with certain medical conditions.
Related Video
Comparison Table
| Company | Product Details | Pros | Cons | Website |
|---|---|---|---|---|
| GC101 in SMA II – Clinical Trials Registry – ICH GCP | GC101 is a gene therapy drug designed for the treatment of Spinal Muscular Atrophy (SMA) Type 2 patients through intrathecal delivery. | – Potential to improve motor milestones in SMA Type 2 patients – Long-term follow-up study to assess sustained efficacy and safety | – Exclusion of patients with prior gene therapy or specific treatments – Potential adverse events and serious adverse events during treatment | ichgcp.net |
| Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment … | GC101 gene therapy drug for the treatment of Spinal Muscular Atrophy Type 3 (SMA 3). | – Evaluates safety and efficacy over a 5-year follow-up. – Conducted in multiple centers in China. | – Excludes patients with certain medical conditions and previous gene therapy tria… – Requires effective contraceptive measures for female patients… | ctv.veeva.com |
| Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment … | GC101 gene therapy drug for the treatment of spinal muscular atrophy Type 1 (SMA 1). | – Evaluates safety and efficacy of gene therapy – Long-term follow-up study of 5 years | – Exclusion of patients with previous gene therapy trials – Potential adverse effects from intrathecal administration | ctv.veeva.com |
| GC101 in Spinal Muscular Atrophy – Clinical Trials Registry – ICH GCP | GC101 is a gene therapy drug designed for the treatment of Spinal Muscular Atrophy (SMA) Type 1 patients through intrathecal delivery. | – Potential to improve motor milestones in SMA Type 1 patients – Long-term follow-up study to assess sustained efficacy | – Exclusion of patients with certain prior treatments or conditions – Limited to specific age group (six months of age and younger) | ichgcp.net |
| Genecradle Therapeutics’ GC101 Injection Recognized as a Breakthrough … | GC101 injection is an AAV gene therapy product for intrathecal administration to treat Type 1, Type 2, and Type 3 spinal muscular atrophy (SMA). | – Significant therapeutic effects and achievement of new motor milestones – One-time treatment with long-term efficacy | – Potential for complications from SMA – Limited to specific types of SMA | en.bj-genecradle.com |
| 获批关键II期临床，君赛GC101 TIL疗法更安全、更优效医药新闻-ByDrug-一站式医药资源共享中心-医药魔方 | GC101 TIL注射液，君赛生物研发的天然TIL细胞疗法，针对晚期黑色素瘤患者。 | – 更安全 – 更优效 | – 信息不足 – 信息不足 | bydrug.pharmcube.com |
| GC-101 by Shanghai Juncell Therapeutics for Metastatic Melanoma … | GC-101 is under clinical development by Shanghai Juncell Therapeutics for the treatment of metastatic melanoma. | – Developed using autologous tumor infiltrating lymphocytes (TILs) – 36% phase transition success rate for Phase II drugs in this indication | – Currently in Phase II, not yet approved – Limited information on long-term efficacy and safety | www.pharmaceutical-technology.com |
| Chinese Medical Journal – LWW | GC101 is a single-dose AAV9-mediated gene therapy for treating SMA type 1 infants via intrathecal injection. | – Demonstrated safety with all adverse events being Grade I or II – Early and sustained improvement in motor function as assessed by CHOP-INTEND | – Limited sample size in the study – Potential confounding factors due to prior treatments with nusinersen | journals.lww.com |
| Treatment of SMA type 1 infants using a single-dose AAV9 … – MedNexus | Generic product details placeholder | – Generic pro 1 – Generic pro 2 | – Generic con 1 – Generic con 2 | mednexus.org |
| Pill Finder: GC 101 White Round – Medicine.com | Acetaminophen 325 mg, white round pill with imprint GC 101. | – Widely used for pain relief. – Available both by prescription and over-the-counter. | – May cause liver damage if overdosed. – Not suitable for individuals with certain medical conditions. | www.medicine.com |
Frequently Asked Questions (FAQs)
What are GC101 factories in China?
GC101 factories refer to manufacturing facilities that adhere to specific guidelines and standards for quality and efficiency. These factories are often involved in producing consumer goods, electronics, and other products, ensuring they meet both local and international regulations.
How do I find a reliable GC101 factory?
To find a reliable GC101 factory, start by researching online directories, trade shows, and industry recommendations. It’s essential to check reviews, request references, and visit the factory if possible to assess their operations and quality control processes.
What types of products are typically made in GC101 factories?
GC101 factories produce a wide range of products, including electronics, textiles, toys, and household items. They focus on high-quality manufacturing processes to ensure that the products meet market demands and safety standards.
Are GC101 factories environmentally friendly?
Many GC101 factories are increasingly adopting eco-friendly practices, such as waste reduction, energy efficiency, and sustainable sourcing. However, it’s important to inquire about a specific factory’s environmental policies to ensure they align with your sustainability goals.
What are the benefits of working with a GC101 factory?
Working with a GC101 factory offers several benefits, including access to skilled labor, advanced manufacturing technologies, and compliance with quality standards. This can lead to improved product quality, faster production times, and better overall value for your business.
